Familial aggregation of Parkinson's disease : A population-based case-control study in Europe
Identifieur interne : 001494 ( PascalFrancis/Corpus ); précédent : 001493; suivant : 001495Familial aggregation of Parkinson's disease : A population-based case-control study in Europe
Auteurs : A. Elbaz ; F. Grigoletto ; M. Baldereschi ; M. M. Breteler ; J. M. Manubens-Bertran ; S. Lopez-Pousa ; J. F. Dartigues ; A. Alperovitch ; C. Tzourio ; W. A. RoccaSource :
- Neurology [ 0028-3878 ] ; 1999.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Article abstract-Objective: To investigate the familial aggregation of PD in a large collaborative population-based case-control study. Background: Most previous case-control studies of the familial aggregation of PD have been hospital-or clinic-based. Methods: We included 219 prevalent cases ascertained in three European populations (centers), using a two-phase design consisting of screening and examination by a neurologist. Each case was matched by age, sex, and center to three controls drawn from the same populations (n = 657). Presence of PD among first-degree relatives (parents and siblings) was determined using the family history approach for 175 cases and 481 controls. Results: Overall, a positive family history (at least one parent or sibling affected by PD) was reported in 10.3% of patients and 3.5% of controls (odds ratio [OR] = 3.2; 95% confidence interval [CI] = 1.6 to 6.6). A similar association was observed when analyses were restricted to nondemented patients and controls (OR = 3.9; 95% CI = 1.7 to 8.7) or to newly diagnosed patients (OR = 3.3; 95% CI = 0.9 to 11.9). We found a significant trend of increasing risk with increasing number of affected relatives (p = 0.003). Analyses stratified by age showed a stronger association for younger PD patients (OR = 7.6; 95% CI = 1.5 to 38.9) than for older patients (OR = 2.5; 95% CI = 1.1 to 5.7). Conclusions: In this large sample of prevalent PD patients and population-matched controls, PD significantly aggregates in families, with the strength of the association being age-dependent. Therefore, familial factors, which can be genetic, environmental, or both, play a role in PD.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
pA |
|
---|
Format Inist (serveur)
NO : | PASCAL 99-0340537 INIST |
---|---|
ET : | Familial aggregation of Parkinson's disease : A population-based case-control study in Europe |
AU : | ELBAZ (A.); GRIGOLETTO (F.); BALDERESCHI (M.); BRETELER (M. M.); MANUBENS-BERTRAN (J. M.); LOPEZ-POUSA (S.); DARTIGUES (J. F.); ALPEROVITCH (A.); TZOURIO (C.); ROCCA (W. A.) |
AF : | INSERM U 360, Recherches Epidémiologiques en Neurologie et Psychopathologie, Hôpital de la Salpêtrière/Paris/France (1 aut., 8 aut., 9 aut.); Institute of Hygiene, University of Padua/Padova/Italie (2 aut.); Targeted Project on Aging, National Research Council/Florence/Italie (3 aut.); Department of Epidemiology and Biostatistics, Erasmus University Medical School/Rotterdam/Pays-Bas (4 aut.); Department of Neurology, University of Navarra/Pamplona/Espagne (5 aut.); Department of Neurology, University Hospital Sta. Caterina/Girona/Espagne (6 aut.); Department of Neurology, Pellegrin Hospital, University of Bordeaux II/France (7 aut.); Departments of Health Sciences Research and Neurology, Mayo Clinic and Mayo Foundation/Rochester, MN/Etats-Unis (10 aut.) |
DT : | Publication en série; Niveau analytique |
SO : | Neurology; ISSN 0028-3878; Coden NEURAI; Etats-Unis; Da. 1999; Vol. 52; No. 9; Pp. 1876-1882; Bibl. 38 ref. |
LA : | Anglais |
EA : | Article abstract-Objective: To investigate the familial aggregation of PD in a large collaborative population-based case-control study. Background: Most previous case-control studies of the familial aggregation of PD have been hospital-or clinic-based. Methods: We included 219 prevalent cases ascertained in three European populations (centers), using a two-phase design consisting of screening and examination by a neurologist. Each case was matched by age, sex, and center to three controls drawn from the same populations (n = 657). Presence of PD among first-degree relatives (parents and siblings) was determined using the family history approach for 175 cases and 481 controls. Results: Overall, a positive family history (at least one parent or sibling affected by PD) was reported in 10.3% of patients and 3.5% of controls (odds ratio [OR] = 3.2; 95% confidence interval [CI] = 1.6 to 6.6). A similar association was observed when analyses were restricted to nondemented patients and controls (OR = 3.9; 95% CI = 1.7 to 8.7) or to newly diagnosed patients (OR = 3.3; 95% CI = 0.9 to 11.9). We found a significant trend of increasing risk with increasing number of affected relatives (p = 0.003). Analyses stratified by age showed a stronger association for younger PD patients (OR = 7.6; 95% CI = 1.5 to 38.9) than for older patients (OR = 2.5; 95% CI = 1.1 to 5.7). Conclusions: In this large sample of prevalent PD patients and population-matched controls, PD significantly aggregates in families, with the strength of the association being age-dependent. Therefore, familial factors, which can be genetic, environmental, or both, play a role in PD. |
CC : | 002B17G |
FD : | Parkinson maladie; Etude familiale; Epidémiologie; Homme; Incidence; Prévalence; Facteur risque; Europe |
FG : | Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative |
ED : | Parkinson disease; Family study; Epidemiology; Human; Incidence; Prevalence; Risk factor; Europe |
EG : | Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease |
SD : | Parkinson enfermedad; Estudio familiar; Epidemiología; Hombre; Incidencia; Prevalencia; Factor riesgo; Europa |
LO : | INIST-6345.354000085281510250 |
ID : | 99-0340537 |
Links to Exploration step
Pascal:99-0340537Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Familial aggregation of Parkinson's disease : A population-based case-control study in Europe</title>
<author><name sortKey="Elbaz, A" sort="Elbaz, A" uniqKey="Elbaz A" first="A." last="Elbaz">A. Elbaz</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM U 360, Recherches Epidémiologiques en Neurologie et Psychopathologie, Hôpital de la Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Grigoletto, F" sort="Grigoletto, F" uniqKey="Grigoletto F" first="F." last="Grigoletto">F. Grigoletto</name>
<affiliation><inist:fA14 i1="02"><s1>Institute of Hygiene, University of Padua</s1>
<s2>Padova</s2>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Baldereschi, M" sort="Baldereschi, M" uniqKey="Baldereschi M" first="M." last="Baldereschi">M. Baldereschi</name>
<affiliation><inist:fA14 i1="03"><s1>Targeted Project on Aging, National Research Council</s1>
<s2>Florence</s2>
<s3>ITA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Breteler, M M" sort="Breteler, M M" uniqKey="Breteler M" first="M. M." last="Breteler">M. M. Breteler</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Epidemiology and Biostatistics, Erasmus University Medical School</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Manubens Bertran, J M" sort="Manubens Bertran, J M" uniqKey="Manubens Bertran J" first="J. M." last="Manubens-Bertran">J. M. Manubens-Bertran</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, University of Navarra</s1>
<s2>Pamplona</s2>
<s3>ESP</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lopez Pousa, S" sort="Lopez Pousa, S" uniqKey="Lopez Pousa S" first="S." last="Lopez-Pousa">S. Lopez-Pousa</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Neurology, University Hospital Sta. Caterina</s1>
<s2>Girona</s2>
<s3>ESP</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dartigues, J F" sort="Dartigues, J F" uniqKey="Dartigues J" first="J. F." last="Dartigues">J. F. Dartigues</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Neurology, Pellegrin Hospital, University of Bordeaux II</s1>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Alperovitch, A" sort="Alperovitch, A" uniqKey="Alperovitch A" first="A." last="Alperovitch">A. Alperovitch</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM U 360, Recherches Epidémiologiques en Neurologie et Psychopathologie, Hôpital de la Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tzourio, C" sort="Tzourio, C" uniqKey="Tzourio C" first="C." last="Tzourio">C. Tzourio</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM U 360, Recherches Epidémiologiques en Neurologie et Psychopathologie, Hôpital de la Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rocca, W A" sort="Rocca, W A" uniqKey="Rocca W" first="W. A." last="Rocca">W. A. Rocca</name>
<affiliation><inist:fA14 i1="08"><s1>Departments of Health Sciences Research and Neurology, Mayo Clinic and Mayo Foundation</s1>
<s2>Rochester, MN</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">99-0340537</idno>
<date when="1999">1999</date>
<idno type="stanalyst">PASCAL 99-0340537 INIST</idno>
<idno type="RBID">Pascal:99-0340537</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001494</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Familial aggregation of Parkinson's disease : A population-based case-control study in Europe</title>
<author><name sortKey="Elbaz, A" sort="Elbaz, A" uniqKey="Elbaz A" first="A." last="Elbaz">A. Elbaz</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM U 360, Recherches Epidémiologiques en Neurologie et Psychopathologie, Hôpital de la Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Grigoletto, F" sort="Grigoletto, F" uniqKey="Grigoletto F" first="F." last="Grigoletto">F. Grigoletto</name>
<affiliation><inist:fA14 i1="02"><s1>Institute of Hygiene, University of Padua</s1>
<s2>Padova</s2>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Baldereschi, M" sort="Baldereschi, M" uniqKey="Baldereschi M" first="M." last="Baldereschi">M. Baldereschi</name>
<affiliation><inist:fA14 i1="03"><s1>Targeted Project on Aging, National Research Council</s1>
<s2>Florence</s2>
<s3>ITA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Breteler, M M" sort="Breteler, M M" uniqKey="Breteler M" first="M. M." last="Breteler">M. M. Breteler</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Epidemiology and Biostatistics, Erasmus University Medical School</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Manubens Bertran, J M" sort="Manubens Bertran, J M" uniqKey="Manubens Bertran J" first="J. M." last="Manubens-Bertran">J. M. Manubens-Bertran</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, University of Navarra</s1>
<s2>Pamplona</s2>
<s3>ESP</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lopez Pousa, S" sort="Lopez Pousa, S" uniqKey="Lopez Pousa S" first="S." last="Lopez-Pousa">S. Lopez-Pousa</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Neurology, University Hospital Sta. Caterina</s1>
<s2>Girona</s2>
<s3>ESP</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dartigues, J F" sort="Dartigues, J F" uniqKey="Dartigues J" first="J. F." last="Dartigues">J. F. Dartigues</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Neurology, Pellegrin Hospital, University of Bordeaux II</s1>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Alperovitch, A" sort="Alperovitch, A" uniqKey="Alperovitch A" first="A." last="Alperovitch">A. Alperovitch</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM U 360, Recherches Epidémiologiques en Neurologie et Psychopathologie, Hôpital de la Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tzourio, C" sort="Tzourio, C" uniqKey="Tzourio C" first="C." last="Tzourio">C. Tzourio</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM U 360, Recherches Epidémiologiques en Neurologie et Psychopathologie, Hôpital de la Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rocca, W A" sort="Rocca, W A" uniqKey="Rocca W" first="W. A." last="Rocca">W. A. Rocca</name>
<affiliation><inist:fA14 i1="08"><s1>Departments of Health Sciences Research and Neurology, Mayo Clinic and Mayo Foundation</s1>
<s2>Rochester, MN</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Neurology</title>
<title level="j" type="abbreviated">Neurology</title>
<idno type="ISSN">0028-3878</idno>
<imprint><date when="1999">1999</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Neurology</title>
<title level="j" type="abbreviated">Neurology</title>
<idno type="ISSN">0028-3878</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Epidemiology</term>
<term>Europe</term>
<term>Family study</term>
<term>Human</term>
<term>Incidence</term>
<term>Parkinson disease</term>
<term>Prevalence</term>
<term>Risk factor</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Etude familiale</term>
<term>Epidémiologie</term>
<term>Homme</term>
<term>Incidence</term>
<term>Prévalence</term>
<term>Facteur risque</term>
<term>Europe</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Article abstract-Objective: To investigate the familial aggregation of PD in a large collaborative population-based case-control study. Background: Most previous case-control studies of the familial aggregation of PD have been hospital-or clinic-based. Methods: We included 219 prevalent cases ascertained in three European populations (centers), using a two-phase design consisting of screening and examination by a neurologist. Each case was matched by age, sex, and center to three controls drawn from the same populations (n = 657). Presence of PD among first-degree relatives (parents and siblings) was determined using the family history approach for 175 cases and 481 controls. Results: Overall, a positive family history (at least one parent or sibling affected by PD) was reported in 10.3% of patients and 3.5% of controls (odds ratio [OR] = 3.2; 95% confidence interval [CI] = 1.6 to 6.6). A similar association was observed when analyses were restricted to nondemented patients and controls (OR = 3.9; 95% CI = 1.7 to 8.7) or to newly diagnosed patients (OR = 3.3; 95% CI = 0.9 to 11.9). We found a significant trend of increasing risk with increasing number of affected relatives (p = 0.003). Analyses stratified by age showed a stronger association for younger PD patients (OR = 7.6; 95% CI = 1.5 to 38.9) than for older patients (OR = 2.5; 95% CI = 1.1 to 5.7). Conclusions: In this large sample of prevalent PD patients and population-matched controls, PD significantly aggregates in families, with the strength of the association being age-dependent. Therefore, familial factors, which can be genetic, environmental, or both, play a role in PD.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0028-3878</s0>
</fA01>
<fA02 i1="01"><s0>NEURAI</s0>
</fA02>
<fA03 i2="1"><s0>Neurology</s0>
</fA03>
<fA05><s2>52</s2>
</fA05>
<fA06><s2>9</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Familial aggregation of Parkinson's disease : A population-based case-control study in Europe</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>ELBAZ (A.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>GRIGOLETTO (F.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>BALDERESCHI (M.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>BRETELER (M. M.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>MANUBENS-BERTRAN (J. M.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>LOPEZ-POUSA (S.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>DARTIGUES (J. F.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>ALPEROVITCH (A.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>TZOURIO (C.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>ROCCA (W. A.)</s1>
</fA11>
<fA14 i1="01"><s1>INSERM U 360, Recherches Epidémiologiques en Neurologie et Psychopathologie, Hôpital de la Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Institute of Hygiene, University of Padua</s1>
<s2>Padova</s2>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Targeted Project on Aging, National Research Council</s1>
<s2>Florence</s2>
<s3>ITA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Epidemiology and Biostatistics, Erasmus University Medical School</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Neurology, University of Navarra</s1>
<s2>Pamplona</s2>
<s3>ESP</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Department of Neurology, University Hospital Sta. Caterina</s1>
<s2>Girona</s2>
<s3>ESP</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department of Neurology, Pellegrin Hospital, University of Bordeaux II</s1>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Departments of Health Sciences Research and Neurology, Mayo Clinic and Mayo Foundation</s1>
<s2>Rochester, MN</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA17 i1="01" i2="1"><s1>EUROPARKINSON Study Group</s1>
<s3>EUR</s3>
</fA17>
<fA20><s1>1876-1882</s1>
</fA20>
<fA21><s1>1999</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>6345</s2>
<s5>354000085281510250</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 1999 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>38 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>99-0340537</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Neurology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Article abstract-Objective: To investigate the familial aggregation of PD in a large collaborative population-based case-control study. Background: Most previous case-control studies of the familial aggregation of PD have been hospital-or clinic-based. Methods: We included 219 prevalent cases ascertained in three European populations (centers), using a two-phase design consisting of screening and examination by a neurologist. Each case was matched by age, sex, and center to three controls drawn from the same populations (n = 657). Presence of PD among first-degree relatives (parents and siblings) was determined using the family history approach for 175 cases and 481 controls. Results: Overall, a positive family history (at least one parent or sibling affected by PD) was reported in 10.3% of patients and 3.5% of controls (odds ratio [OR] = 3.2; 95% confidence interval [CI] = 1.6 to 6.6). A similar association was observed when analyses were restricted to nondemented patients and controls (OR = 3.9; 95% CI = 1.7 to 8.7) or to newly diagnosed patients (OR = 3.3; 95% CI = 0.9 to 11.9). We found a significant trend of increasing risk with increasing number of affected relatives (p = 0.003). Analyses stratified by age showed a stronger association for younger PD patients (OR = 7.6; 95% CI = 1.5 to 38.9) than for older patients (OR = 2.5; 95% CI = 1.1 to 5.7). Conclusions: In this large sample of prevalent PD patients and population-matched controls, PD significantly aggregates in families, with the strength of the association being age-dependent. Therefore, familial factors, which can be genetic, environmental, or both, play a role in PD.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Etude familiale</s0>
<s5>16</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Family study</s0>
<s5>16</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Estudio familiar</s0>
<s5>16</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Epidémiologie</s0>
<s5>17</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Epidemiology</s0>
<s5>17</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Epidemiología</s0>
<s5>17</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Incidence</s0>
<s5>23</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Incidence</s0>
<s5>23</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Incidencia</s0>
<s5>23</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Prévalence</s0>
<s5>24</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Prevalence</s0>
<s5>24</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Prevalencia</s0>
<s5>24</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Facteur risque</s0>
<s5>35</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Risk factor</s0>
<s5>35</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Factor riesgo</s0>
<s5>35</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Europe</s0>
<s2>NG</s2>
<s5>36</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Europe</s0>
<s2>NG</s2>
<s5>36</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Europa</s0>
<s2>NG</s2>
<s5>36</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fN21><s1>214</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 99-0340537 INIST</NO>
<ET>Familial aggregation of Parkinson's disease : A population-based case-control study in Europe</ET>
<AU>ELBAZ (A.); GRIGOLETTO (F.); BALDERESCHI (M.); BRETELER (M. M.); MANUBENS-BERTRAN (J. M.); LOPEZ-POUSA (S.); DARTIGUES (J. F.); ALPEROVITCH (A.); TZOURIO (C.); ROCCA (W. A.)</AU>
<AF>INSERM U 360, Recherches Epidémiologiques en Neurologie et Psychopathologie, Hôpital de la Salpêtrière/Paris/France (1 aut., 8 aut., 9 aut.); Institute of Hygiene, University of Padua/Padova/Italie (2 aut.); Targeted Project on Aging, National Research Council/Florence/Italie (3 aut.); Department of Epidemiology and Biostatistics, Erasmus University Medical School/Rotterdam/Pays-Bas (4 aut.); Department of Neurology, University of Navarra/Pamplona/Espagne (5 aut.); Department of Neurology, University Hospital Sta. Caterina/Girona/Espagne (6 aut.); Department of Neurology, Pellegrin Hospital, University of Bordeaux II/France (7 aut.); Departments of Health Sciences Research and Neurology, Mayo Clinic and Mayo Foundation/Rochester, MN/Etats-Unis (10 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Neurology; ISSN 0028-3878; Coden NEURAI; Etats-Unis; Da. 1999; Vol. 52; No. 9; Pp. 1876-1882; Bibl. 38 ref.</SO>
<LA>Anglais</LA>
<EA>Article abstract-Objective: To investigate the familial aggregation of PD in a large collaborative population-based case-control study. Background: Most previous case-control studies of the familial aggregation of PD have been hospital-or clinic-based. Methods: We included 219 prevalent cases ascertained in three European populations (centers), using a two-phase design consisting of screening and examination by a neurologist. Each case was matched by age, sex, and center to three controls drawn from the same populations (n = 657). Presence of PD among first-degree relatives (parents and siblings) was determined using the family history approach for 175 cases and 481 controls. Results: Overall, a positive family history (at least one parent or sibling affected by PD) was reported in 10.3% of patients and 3.5% of controls (odds ratio [OR] = 3.2; 95% confidence interval [CI] = 1.6 to 6.6). A similar association was observed when analyses were restricted to nondemented patients and controls (OR = 3.9; 95% CI = 1.7 to 8.7) or to newly diagnosed patients (OR = 3.3; 95% CI = 0.9 to 11.9). We found a significant trend of increasing risk with increasing number of affected relatives (p = 0.003). Analyses stratified by age showed a stronger association for younger PD patients (OR = 7.6; 95% CI = 1.5 to 38.9) than for older patients (OR = 2.5; 95% CI = 1.1 to 5.7). Conclusions: In this large sample of prevalent PD patients and population-matched controls, PD significantly aggregates in families, with the strength of the association being age-dependent. Therefore, familial factors, which can be genetic, environmental, or both, play a role in PD.</EA>
<CC>002B17G</CC>
<FD>Parkinson maladie; Etude familiale; Epidémiologie; Homme; Incidence; Prévalence; Facteur risque; Europe</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative</FG>
<ED>Parkinson disease; Family study; Epidemiology; Human; Incidence; Prevalence; Risk factor; Europe</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease</EG>
<SD>Parkinson enfermedad; Estudio familiar; Epidemiología; Hombre; Incidencia; Prevalencia; Factor riesgo; Europa</SD>
<LO>INIST-6345.354000085281510250</LO>
<ID>99-0340537</ID>
</server>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001494 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001494 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= PascalFrancis |étape= Corpus |type= RBID |clé= Pascal:99-0340537 |texte= Familial aggregation of Parkinson's disease : A population-based case-control study in Europe }}
![]() | This area was generated with Dilib version V0.6.29. | ![]() |